| Charles V Duss, MD | |
|
3316 3rd St S, Suite 103, Jacksonville, FL 32250-6073 | |
| (904) 241-7865 | |
| Not Available |
| Full Name | Charles V Duss |
|---|---|
| Gender | Male |
| Speciality | Ophthalmology |
| Experience | 21 Years |
| Location | 3316 3rd St S, Jacksonville, Florida |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1043356538 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207W00000X | Ophthalmology | ME97514 (Florida) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Atlantic Eye Institute, P.a. | 2466434386 | 9 |
News Archive
Onyx Pharmaceuticals, Inc. today announced results from a Bayer HealthCare Pharmaceuticals Phase 3 trial evaluating the investigational compound regorafenib (BAY 73-4506) for the treatment of patients with metastatic colorectal cancer (mCRC) whose disease has progressed after approved standard therapies.
According to a study published in the July 15 issue of the Journal of Clinical Oncology, genes expressed in benign tissue adjacent to prostate cancer tissue are much more similar to those expressed in prostate cancer tissue than previously thought.
In a new UCSF study of more than 2 million mammogram screenings performed on nearly 700,000 women in the United States, scientists for the first time show a direct link between reduced hormone therapy and declines in ductal carcinoma in situ (DCIS) as well as invasive breast cancer. The researchers saw such a striking decrease, they believe they also have uncovered indirect evidence that hormones promote breast tumor growth.
The U.S. Food and Drug Administration is alerting clinical laboratory staff and health care providers that the FDA is monitoring the potential impact of viral mutations, including an emerging variant from the United Kingdom known as the B.1.1.7 variant, on authorized SARS-CoV-2 molecular tests, and that false negative results can occur with any molecular test for the detection of SARS-CoV-2 if a mutation occurs in the part of the virus's genome assessed by that test.
Noting the WHO and the Global Fund to Fight AIDS, Tuberculosis and Malaria on Monday issued a joint statement calling for an additional $1.6 million a year to fight tuberculosis (TB) in low- and middle-income countries, GlobalPost's "Global Pulse" blog examines the global impact of childhood TB, writing, "While health officials did not single out the devastating impact of the disease on children ... WHO estimates that at least 500,000 children contract TB each year and that 70,000 die from the disease, largely in Asia and Africa."
› Verified 8 days ago
| Entity Name | Atlantic Eye Institute, P.a. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1033200241 PECOS PAC ID: 2466434386 Enrollment ID: O20040603001518 |
News Archive
Onyx Pharmaceuticals, Inc. today announced results from a Bayer HealthCare Pharmaceuticals Phase 3 trial evaluating the investigational compound regorafenib (BAY 73-4506) for the treatment of patients with metastatic colorectal cancer (mCRC) whose disease has progressed after approved standard therapies.
According to a study published in the July 15 issue of the Journal of Clinical Oncology, genes expressed in benign tissue adjacent to prostate cancer tissue are much more similar to those expressed in prostate cancer tissue than previously thought.
In a new UCSF study of more than 2 million mammogram screenings performed on nearly 700,000 women in the United States, scientists for the first time show a direct link between reduced hormone therapy and declines in ductal carcinoma in situ (DCIS) as well as invasive breast cancer. The researchers saw such a striking decrease, they believe they also have uncovered indirect evidence that hormones promote breast tumor growth.
The U.S. Food and Drug Administration is alerting clinical laboratory staff and health care providers that the FDA is monitoring the potential impact of viral mutations, including an emerging variant from the United Kingdom known as the B.1.1.7 variant, on authorized SARS-CoV-2 molecular tests, and that false negative results can occur with any molecular test for the detection of SARS-CoV-2 if a mutation occurs in the part of the virus's genome assessed by that test.
Noting the WHO and the Global Fund to Fight AIDS, Tuberculosis and Malaria on Monday issued a joint statement calling for an additional $1.6 million a year to fight tuberculosis (TB) in low- and middle-income countries, GlobalPost's "Global Pulse" blog examines the global impact of childhood TB, writing, "While health officials did not single out the devastating impact of the disease on children ... WHO estimates that at least 500,000 children contract TB each year and that 70,000 die from the disease, largely in Asia and Africa."
› Verified 8 days ago
| Entity Name | Harris Wilcox And Donovan Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023120409 PECOS PAC ID: 4981776333 Enrollment ID: O20080701000167 |
News Archive
Onyx Pharmaceuticals, Inc. today announced results from a Bayer HealthCare Pharmaceuticals Phase 3 trial evaluating the investigational compound regorafenib (BAY 73-4506) for the treatment of patients with metastatic colorectal cancer (mCRC) whose disease has progressed after approved standard therapies.
According to a study published in the July 15 issue of the Journal of Clinical Oncology, genes expressed in benign tissue adjacent to prostate cancer tissue are much more similar to those expressed in prostate cancer tissue than previously thought.
In a new UCSF study of more than 2 million mammogram screenings performed on nearly 700,000 women in the United States, scientists for the first time show a direct link between reduced hormone therapy and declines in ductal carcinoma in situ (DCIS) as well as invasive breast cancer. The researchers saw such a striking decrease, they believe they also have uncovered indirect evidence that hormones promote breast tumor growth.
The U.S. Food and Drug Administration is alerting clinical laboratory staff and health care providers that the FDA is monitoring the potential impact of viral mutations, including an emerging variant from the United Kingdom known as the B.1.1.7 variant, on authorized SARS-CoV-2 molecular tests, and that false negative results can occur with any molecular test for the detection of SARS-CoV-2 if a mutation occurs in the part of the virus's genome assessed by that test.
Noting the WHO and the Global Fund to Fight AIDS, Tuberculosis and Malaria on Monday issued a joint statement calling for an additional $1.6 million a year to fight tuberculosis (TB) in low- and middle-income countries, GlobalPost's "Global Pulse" blog examines the global impact of childhood TB, writing, "While health officials did not single out the devastating impact of the disease on children ... WHO estimates that at least 500,000 children contract TB each year and that 70,000 die from the disease, largely in Asia and Africa."
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Charles V Duss, MD 3316 3rd St S, Suite 103, Jacksonville, FL 32250-6073 Ph: (904) 241-7865 | Charles V Duss, MD 3316 3rd St S, Suite 103, Jacksonville, FL 32250-6073 Ph: (904) 241-7865 |
News Archive
Onyx Pharmaceuticals, Inc. today announced results from a Bayer HealthCare Pharmaceuticals Phase 3 trial evaluating the investigational compound regorafenib (BAY 73-4506) for the treatment of patients with metastatic colorectal cancer (mCRC) whose disease has progressed after approved standard therapies.
According to a study published in the July 15 issue of the Journal of Clinical Oncology, genes expressed in benign tissue adjacent to prostate cancer tissue are much more similar to those expressed in prostate cancer tissue than previously thought.
In a new UCSF study of more than 2 million mammogram screenings performed on nearly 700,000 women in the United States, scientists for the first time show a direct link between reduced hormone therapy and declines in ductal carcinoma in situ (DCIS) as well as invasive breast cancer. The researchers saw such a striking decrease, they believe they also have uncovered indirect evidence that hormones promote breast tumor growth.
The U.S. Food and Drug Administration is alerting clinical laboratory staff and health care providers that the FDA is monitoring the potential impact of viral mutations, including an emerging variant from the United Kingdom known as the B.1.1.7 variant, on authorized SARS-CoV-2 molecular tests, and that false negative results can occur with any molecular test for the detection of SARS-CoV-2 if a mutation occurs in the part of the virus's genome assessed by that test.
Noting the WHO and the Global Fund to Fight AIDS, Tuberculosis and Malaria on Monday issued a joint statement calling for an additional $1.6 million a year to fight tuberculosis (TB) in low- and middle-income countries, GlobalPost's "Global Pulse" blog examines the global impact of childhood TB, writing, "While health officials did not single out the devastating impact of the disease on children ... WHO estimates that at least 500,000 children contract TB each year and that 70,000 die from the disease, largely in Asia and Africa."
› Verified 8 days ago
Jeffrey Herschel Levenson, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 751 Oak St Ste 200, Jacksonville, FL 32204 Phone: 904-366-3781 | |
Dr. Don Kent Davis Jr., M.D. Ophthalmology Medicare: May Accept Medicare Assignments Practice Location: 580 W 8th St, Tower Ii, Floor Iii, Jacksonville, FL 32209 Phone: 904-244-9361 Fax: 904-244-9391 | |
Frank Wilson Mcdonald, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 751 Oak St, 200, Jacksonville, FL 32204 Phone: 904-366-3781 | |
Dr. Kenzo James Paul Koike, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 11512 Lake Mead Ave Unit 534, Jacksonville, FL 32256 Phone: 904-564-2020 | |
Dr. Adam David Koenigsberg, MD Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 8833 Perimeter Park Blvd, # 403, Jacksonville, FL 32216 Phone: 904-996-7774 Fax: 904-996-9511 | |
Dr. Rachana Ashok Patel, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 13453 N Main St Ste 306, Jacksonville, FL 32218 Phone: 904-564-2020 Fax: 904-683-3934 |